恩替卡韦对乙型肝炎后肝硬化患者肝功能及肿瘤标志物的影响研究  

Study on the effect of liver function and tumor marker of patients with liver cirrhosis after hepatitis B by nucleoside drugs Entecavir

作　　者：肖兴国[1] 吴慧丽[1] 李琨琨[1] 

机构地区：[1]郑州大学附属郑州中心医院消化内科,河南郑州450007

出　　处：《中国生化药物杂志》2015年第4期88-90,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨核苷类药物恩替卡韦对乙型肝炎后肝硬化患者肝功能及肿瘤标志物的影响。方法选取乙型肝炎后肝硬化患者90例,按随机数字表分为实验组与对照组,每组各45例,比较治疗前后各组患者的肝功能及肿瘤标志物水平。结果与对照组相比,实验组的HBV DNA水平较低,转阴率明显升高(P<0.05);与对照组相比,实验组ALT、AST、TBi L水平显著上升(P<0.05),Ch E、Al B水平均显著降低(P<0.05);与对照组相比,实验组CEA、AFP、CA125和CA199水平较低(P<0.05)。结论核苷类药物能够明显改善乙型肝炎后肝硬化患者肝功能及肿瘤标志物各指标水平,对乙型肝炎后肝硬化的治疗有指导意义。Objective To investigate the effects of liver function and tumor markers by nucleoside analogues Entecavir on patients with liver cirrhosis after hepatitis B.Methods 90 patients with liver cirrhosis after hepatitis B were selected, according to the different drugs were divided into experimental group and control group.Liver function and levels of tumor markers were compared after experiment.Results Two groups of patients with male to female ratio, average age, course of disease, no significant difference in general data of hepatitis B virus DNA content, comparable （P〉0.05）;Compared with the control group, the experimental group HBV DNA level is low, the negative rate was significantly higher （P〈0.05）;Compared with the control group, the experimental group ALT, AST and TBiL levels were significantly increased（P〈0.05）, ChE, AlB were significantly decreased （P〈0.05）;Compared with the control group, the experimental group CEA, AFP, CA125 and lower CA199 levels （P〈0.05）.Conclusion Nucleoside drugs can significantly improve liver function in patients with liver cirrhosis after hepatitis Band tumor markers indicators, and it is significance for treatment of liver cirrhosis after hepatitis.

关 键 词：核苷类药物 乙型肝炎后肝硬化 肝功能 肿瘤标志物 

分 类 号：R575[医药卫生—消化系统]